4SC Investor

4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases.

Invests into

Industry: Energetic Process
Headquarters: Germany
Founded Date: 1997
Employees Number: 51-100
Funding Status: IPO
Investors Number: 9
Total Funding: 94700000 EUR
Estimated Revenue: $1M to $10M
Last Funding Date: 2019-11-12
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership